Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||FGFR3 S131L|
|Indication/Tumor Type||head and neck squamous cell carcinoma|
|Response Type||decreased response|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FGFR3 S131L||head and neck squamous cell carcinoma||decreased response||Infigratinib||Preclinical - Cell culture||Actionable||In a preclinical study, a head and neck squamous cell carcinoma cell line expressing FGFR3 S131L demonstrated decreased sensitivity to Truseltiq (infigratinib) compared to cells expressing wild-type FGFR3 in culture (PMID: 27053219).||27053219|
|PubMed Id||Reference Title||Details|
|(27053219)||Evaluation of FGFR3 as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma.||Full reference...|